Pharmaceutical developer Johnson & Johnson is seeking emergency use authorization from the Food and Drug Administration for its COVID-19 booster vaccine for people 18 years and older.

The company claims that a booster dose given six months after the initial one-dose regimen increases antibodies 12 times during the first month following administration of the booster and is 94% effective against symptomatic infection.

Recommended Stories

FDA greenlights Pfizer vaccine boosters for 16- and 17-year-olds

CDC director: Boosters may force change to definition of ‘fully vaccinated’

COVID-19 vaccines: The latest on recommendations and public attitudes